Lorem, a nonprofit foundation, today announced that nine patients with an ultra-rare type of amyotrophic lateral sclerosis (ALS) have been treated during the first year of a multi-year grant from the ...
The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.